The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria

Br J Dermatol. 2003 Mar;148(3):604-6. doi: 10.1046/j.1365-2133.2003.05209_12.x.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Chronic Disease
  • Cyclooxygenase Inhibitors / therapeutic use*
  • Female
  • Histamine Release / drug effects
  • Humans
  • Lactones / therapeutic use*
  • Male
  • Middle Aged
  • Sulfones
  • Urticaria / drug therapy*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib